Additionally, hepatic transcriptomic analyses revealed that the amelioration of NASH likely occurred via regulation of inflammatory- and fibrosis-related responses, and an integrated analysis of transcriptional and non-transcriptional genes regulated by telmisartan identified cross-talk between angiotensin-PPAR-NFκB pathways that could contribute to the effects of telmisartan on NASH. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.